The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

7 Ways Hepatitis C Affects Women Differently than Men

Back to News Homepage

Next

Racing to Shorten Duration of Hep C Treatment

Phase I Clinical Trial for Hepatitis C Drug Starts: ACH-3422

June 12, 2014

Print this page

Find out about a new phase I clinical trial that Achillion Pharmaceuticals Inc. has initiated for its Hepatitis C drug candidate, ACH-3422.

Achillion Pharmaceuticals Inc. announced the company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV. Sovaprevir doses of 200 mg once daily, the previously evaluated dose that was well-tolerated with clinical activity in two completed Phase 2 studies, may be used in additional therapeutic clinical trials.

Continue reading this entire article:
http://www.dddmag.com/news/2014/06/achillion-kicks-phase-1-trial-hep-c-drug

7 Comments
Share
Share

Previous

7 Ways Hepatitis C Affects Women Differently than Men

Back to News Homepage

Next

Racing to Shorten Duration of Hep C Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.